Isoindoline compositions and methods for treating neurodegenerative disease
AssigneeCognition Therapeutics, Inc.
InventorsGilbert M. Rishton, Susan M. Catalano, Gary C. Look
Life of this patent
Estimating the term…
Abstract
Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
Claims20
A method of treating Alzheimer's disease comprising administering to a subject having said disease a dose of about 0.01 mg/kg/day to about 25 mg/kg/day, of a compound of the Formula:
- or a pharmaceutically acceptable salt thereof.
A method of treating Alzheimer's disease comprising administering to a subject having said disease a pharmaceutical composition comprising a compound of the Formula:
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, wherein a dose of the compound or pharmaceutically acceptable salt thereof is administered is 0.01 mg/kg/day to about 25 mg/kg/day.
Dependencies are inferred from the claim text.